Advances in biological therapies for hidradenitis suppurativa
-
摘要: 化脓性汗腺炎是一种发生在腋窝、腹股沟、臀部、肛周等皮肤褶皱部位的慢性复发性炎症性皮肤病。该病好发于年轻女性，主要的临床表现为疼痛性炎性结节、脓肿、破溃以及窦道和瘢痕形成。该病病程长且反复发作，严重影响患者的生活质量。化脓性汗腺炎还可与其他代谢性疾病或心血管疾病并发，缩短患者的寿命。化脓性汗腺炎的确切发病机制目前仍不清楚，学术界认为包括遗传因素在内的多种因素起综合的致病作用。目前化脓性汗腺炎的治疗手段限于抗感染以及其他对症治疗措施，故而治疗效果有限。现主流观点认为异常激活的免疫系统，包括异常升高的TNF-α、IL-17、IL-12、IL-23等细胞因子，可能在其发病过程中发挥着重要作用。随着对化脓性汗腺炎病理生理过程的了解，以及对于并发其他炎症性疾病的患者进行生物治疗有效性的观察，对化脓性汗腺炎的生物治疗获得了广泛的关注。基于多项临床试验的结果，美国FDA批准了抗TNF-α单克隆抗体阿达木单抗作为治疗化脓性汗腺炎的唯一生物制剂。同时，以上述炎症细胞因子为靶标的其他生物制剂也在中重度化脓性汗腺炎的治疗中显示了良好的疗效和安全性。本文在简单介绍化脓性汗腺炎的基础上，主要对化脓性汗腺炎所涉及的免疫因子的靶向生物治疗进展作一综述。Abstract: Hidradenitis suppurativa is a chronic recurrent inflammatory skin disease, which occurs in the skin folds of axillary, inguinal, gluteal and perianal areas. The disease is often seen in young females, which is characterised by inflammatory nodules, abscesses, fistulae and scars. Patients with hidradenitis suppurativa have a long disease history and a reduced quality of life. Although its pathogenesis is still unclear, hidradenitis suppurativa is considered as a result of interactions between genetic factors and other environmental factors. At present, the therapeutic options are limited to antibiotics and other symptom-relieving measures. Aberrant immune responses, including increased cytokines, such as TNF-α, IL-17, IL-12 and IL-23, may play an important role. Considering that the pathogenetic mechanisms are understood, and observations are made when patients with concurrent hidradenitis suppurativa are treated with biological agents, biological treatment has gained considerable attention. Adalimumab, an anti-TNF-α monoclonal antibody, is currently the only biological agent approved by the US FDA based on the results of several clinical trials, which can treat hidradenitis suppurativa, but other biological agents targeting these inflammatory cytokines have also shown good efficacy and safety in the treatment of moderate-to-severe hidradenitis suppurativa. Based on a brief introduction to hidradenitis suppurativa, this review summarises advances in the biological therapy targeting immune factors involved in hidradenitis suppurativa.
-
Key words:
- Hidradenitis suppurativa /
- Therapy /
- Biological agents
-
表 1 应用于HS的生物制剂和小分子抑制剂
药物名称 靶标 性质 最高临床研究等级 阿达木单抗 TNF-α 全人源化IgG1单克隆抗体 Ⅲ期随机双盲对照 英夫利昔单抗 TNF-α 人鼠嵌合IgG1单克隆抗体 随机双盲对照 依那西普 TNF-α受体 二聚TNF- α受体拮抗剂 随机双盲对照 阿那白滞素 IL-1受体 人重组形式的IL-1受体拮抗剂 随机双盲对照 Bermekimab(MABp1) IL-1α 人源化IgG1单克隆抗体 随机双盲对照 Canakinumab IL-1β 人源化IgG1单克隆抗体 病例系列 司库奇尤单抗 IL-17A 全人源化IgG1单克隆抗体 开放标签试验 依奇珠单抗 IL-17A 人源化IgG4单克隆抗体 病例系列 布罗达单抗 IL-17RA 人源化IgG2单克隆抗体 队列研究 乌司奴单抗 IL-12/IL-23p40 全人源化IgG1单克隆抗体 队列研究 古塞奇尤单抗 IL-23 全人源化IgG1单克隆抗体 病例系列 IFX-1 补体C5a IgG4单克隆抗体 Ⅱa临床试验 
下载: 导出CSV
-
[1] SABAT R, JEMEC G B E, MATUSIAK Ł, et al. Hidradenitis suppurativa[J]. Nat Rev Dis Primers, 2020, 6(1): 18. doi: 10.1038/s41572-020-0149-1 [2] KALLIOLIAS G D, IVASHKIV L B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies[J]. Nat Rev Rheumatol, 2016, 12(1): 49-62. doi: 10.1038/nrrheum.2015.169 [3] KIMBALL A B, OKUN M M, WILLIAMS D A, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa[J]. N Engl J Med, 2016, 375(5): 422-434. doi: 10.1056/NEJMoa1504370 [4] ZOUBOULIS C C, OKUN M M, PRENS E P, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study[J]. J Am Acad Dermatol, 2019, 80(1): 60-69. doi: 10.1016/j.jaad.2018.05.040 [5] MORITA A, TAKAHASHI H, OZAWA K, et al. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa[J]. J Dermatol, 2019, 46(9): 745-751. doi: 10.1111/1346-8138.14997 [6] ZOUBOULIS C C. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa[J]. Expert Rev Clin Immunol, 2016, 12(10): 1015-1026. doi: 10.1080/1744666X.2016.1221762 [7] GRANT A, GONZALEZ T, MONTGOMERY M O, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial[J]. J Am Acad Dermatol, 2010, 62(2): 205-217. doi: 10.1016/j.jaad.2009.06.050 [8] ADAMS D R, YANKURA J A, FOGELBERG A C, et al. Treatment of hidradenitis suppurativa with etanercept injection[J]. Arch Dermatol, 2010, 146(5): 501-504. http://www.practicalreviews.com/My_Media/PDF/Dermatology,%20July%2030%202010.pdf [9] WITTE-HANDEL E, WOLK K, TSAOUSI A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction[J]. J Invest Dermatol, 2019, 139(6): 1294-1305. doi: 10.1016/j.jid.2018.11.018 [10] TZANETAKOU V, KANNI T, GIATRAKOU S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial[J]. JAMA Dermatol, 2016, 152(1): 52-59. doi: 10.1001/jamadermatol.2015.3903 [11] BANERJEE A, MCNISH S, SHANMUGAM V K. Interferon-gamma (IFN-γ) is elevated in wound exudate from hidradenitis suppurativa[J]. Immunol Invest, 2017, 46(2): 149-158. doi: 10.1080/08820139.2016.1230867 [12] MENIS D, MAROÑAS-JIMÉNEZ L, DELGADO-MARQUEZ A M, et al. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy[J]. Br J Dermatol, 2015, 172(3): 810-811. doi: 10.1111/bjd.13292 [13] KANNI T, ARGYROPOULOU M, SPYRIDOPOULOS T, et al. MABp1 Targeting IL-1alpha for Moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study[J]. J Invest Dermatol, 2018, 138(4): 795-801. doi: 10.1016/j.jid.2017.10.030 [14] GOTTLIEB A, NATSIS N E, KERDEL F, et al. A Phase Ⅱ open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain[J]. J Invest Dermatol, 2020, 140(8): 1538-1545. doi: 10.1016/j.jid.2019.10.024 [15] THOMI R, CAZZANIGA S, SEYED JAFARI S M, et al. Association of hidradenitis suppurativa with T Helper 1/T Helper 17 phenotypes: a semantic map analysis[J]. JAMA Dermatol, 2018, 154(5): 592-595. doi: 10.1001/jamadermatol.2018.0141 [16] BLOK J L, LI K, BRODMERKEL C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum[J]. Br J Dermatol, 2016, 174(4): 839-846. doi: 10.1111/bjd.14338 [17] CASSERES R G, PRUSSICK L, ZANCANARO P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial[J]. J Am Acad Dermatol, 2020, 82(6): 1524-1526. doi: 10.1016/j.jaad.2020.02.005 [18] COTTER C, TOBIN A M, O'CONNOR R, et al. Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports[J]. Br J Dermatol, 2018, 179: 70. doi: 10.1111/bjd.16861 [19] FREW J W, NAVRAZHINA K, GRAND D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study[J]. J Am Acad Dermatol, 2020, 83(5): 1341-1348. doi: 10.1016/j.jaad.2020.05.007 [20] CASSERES R G, KAHN J S, HER M J, et al. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review[J]. J Am Acad Dermatol, 2019, 81(1): 265-267. doi: 10.1016/j.jaad.2018.12.017 [21] GIAMARELLOS-BOURBOULIS E J, ARGYROPOULOU M, KANNI T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab[J]. Br J Dermatol, 2020, 183(1): 176-178. doi: 10.1111/bjd.18877 [22] ZOUBOULIS C C, BECHARA F G, DICKINSON-BLOK J L, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization-systematic review and recommendations from the HS ALLIANCE working group[J]. J Eur Acad Dermatol Venereol, 2019, 33(1): 19-31. doi: 10.1111/jdv.15233 [23] ALIKHAN A, SAYED C, ALAVI A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part Ⅱ: Topical, intralesional, and systemic medical management[J]. J Am Acad Dermatol, 2019, 81(1): 91-101. doi: 10.1016/j.jaad.2019.02.068 [24] ZOUBOULIS C C, DESAI N, EMTESTAM L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa[J]. J Eur Acad Dermatol Venereol, 2015, 29(4): 619-644. doi: 10.1111/jdv.12966 [25] INGRAM J R, COLLIER F, BROWN D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018[J]. Br J Dermatol, 2019, 180(5): 1009-1017. doi: 10.1111/bjd.17537 [26] HUNGER R E, LAFFITTE E, LAUCHLI S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa[J]. Dermatology, 2017, 233(2-3): 113-119. doi: 10.1159/000477459 [27] ALAVI A, LYNDE C, ALHUSAYEN R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document[J]. J Cutan Med Surg, 2017, 21(6): 513-524. doi: 10.1177/1203475417716117 [28] GULLIVER W, LANDELLS I D R, MORGAN D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease[J]. J Cutan Med Surg, 2018, 22(1): 71-77. doi: 10.1177/1203475417736290 [29] MAGALHÀES R F, RIVITTI-MACHADO M C, DUARTE G V, et al. Consensus on the treatment of hidradenitis suppurativa-Brazilian Society of Dermatology[J]. An Bras Dermatol, 2019, 94(2 Suppl 1): 7-19. doi: 10.1590/abd1806-4841.20198607 [30] DEFAZIO M V, ECONOMIDES J M, KING K S, et al. Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa[J]. Ann Plast Surg, 2016, 77(2): 217-222. doi: 10.1097/SAP.0000000000000584 [31] VULLIEMOZ M, BRAND S, JUILLERAT P, et al. TNF-Alpha Blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update[J]. Digestion, 2020, 101 Suppl 1: 16-26. http://www.researchgate.net/publication/343352574_TNF-Alpha_Blockers_in_Inflammatory_Bowel_Diseases_Practical_Recommendations_and_a_User's_Guide_An_Update -
点击查看大图
表(2)
计量
- 文章访问数: 259
- HTML全文浏览量: 264
- PDF下载量: 13
- 被引次数: 0
